Christopher Thomas Giordano - 13 Jul 2026 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Reporting relationship: CEO, Director
Issuer ticker: TENX
Reported as of: 13 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jul 2026, 19:29:41 UTC
Prior SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ S. Halle Vakani, as Attorney-in-Fact

Key filing fact

Christopher Thomas Giordano filed Form 4 for TENAX THERAPEUTICS, INC. (TENX) on 14 Jul 2026.

Key facts

This page summarizes Christopher Thomas Giordano's Form 4 filing for TENAX THERAPEUTICS, INC. (TENX).
4 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 14 Jul 2026, 19:29.

Change

Previous filing in this sequence was filed on 13 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001871714 Primary reporting owner

Giordano Christopher Thomas

Relationship: CEO, Director
Address: 101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL
Signature: /s/ S. Halle Vakani, as Attorney-in-Fact
Signature date: 14 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TENX transaction

Common Stock

Options Exercise

Transaction value
Shares: +219
Change %: +8.4%
Price: $3.55^*
Shares after: 2,824
Date: 13 Jul 2026
Ownership: Direct
Footnotes: F1

TENX transaction

Common Stock

Options Exercise

Transaction value
Shares: +8,500
Change %: +301%
Price: $5.94^*
Shares after: 11,324
Date: 13 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TENX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -219
Change %: -50%
Price: $0.000000^*
Shares after: 218
Date: 13 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 219
Exercise price: $3.55
Footnotes: F2

TENX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -8,500
Change %: -0.68%
Price: $0.000000^*
Shares after: 1,241,500
Date: 13 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,500
Exercise price: $5.94

TENX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 450,000
Date: 13 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 450,000
Exercise price: $13.30
Footnotes: F3

TENX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,400,000
Date: 13 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,400,000
Exercise price: $5.89
Footnotes: F4

TENX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 125
Date: 13 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125
Exercise price: $992.00
Footnotes: F5

TENX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 157
Date: 13 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 157
Exercise price: $3152.00
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The aggregate exercise price was paid in cash.

Footnote F2

The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.

Footnote F3

The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.

Footnote F4

The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.

Footnote F5

The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.

Footnote F6

The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.